SciClone Pharmaceuticals (NASDAQ: SCLN) and Aegerion Pharmaceuticals (NASDAQ:AEGR) are both small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
Earnings and Valuation
This table compares SciClone Pharmaceuticals and Aegerion Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Insider & Institutional Ownership
72.8% of SciClone Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.9% of Aegerion Pharmaceuticals shares are owned by institutional investors. 5.2% of SciClone Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Aegerion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares SciClone Pharmaceuticals and Aegerion Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for SciClone Pharmaceuticals and Aegerion Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SciClone Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 25.56%. Given SciClone Pharmaceuticals’ higher possible upside, research analysts plainly believe SciClone Pharmaceuticals is more favorable than Aegerion Pharmaceuticals.
SciClone Pharmaceuticals beats Aegerion Pharmaceuticals on 5 of the 6 factors compared between the two stocks.
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
Receive News & Ratings for SciClone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.